This analysis explores the binding affinity of compounds from curcuma aeruginosa roxb against braf v600e in melanoma, indicating potential for further development.
Key Points
The study shows several compounds from curcuma aeruginosa roxb exhibit varying potential as braf v600e inhibitors.
Docking validation revealed the best binding affinity for certain compounds, but none matched vemurafenib's effectiveness.
Molecular docking methods were employed to assess the interactions between compounds and the braf v600e receptor.
Findings emphasize further structural development is necessary to enhance the compounds' anticancer activity.